Financial and Earnings Updates
MINISO Group (MNSO) delivered strong FY2024 results with revenue rising 22.8% to RMB17.0 billion and a record gross margin of 44.9%, reflecting accelerated global expansion.
NIO Inc. (NIO) showcased impressive Q4 performance with vehicle deliveries surging 45.2% YoY, underlining its robust market position.
Carnival Corporation (CCL) reported record‐setting Q1 2025 results with revenues reaching $5.8 billion and an operating income of $543 million, prompting an upgraded full‐year outlook.
MicroCloud Hologram Inc. (HOLO) filed its 2024 annual report, with operating revenue climbing 42.16% to RMB290 million and a dramatic surge in cash equivalents by 575.54%; read the company’s full report.
Tivic Health Systems (TIVC) reported its year‐end 2024 results amid a transformative period, securing exclusive license rights and a $25M equity line of credit while reducing net loss by 30% to $5.7M; more details are available in the full report.
ParaZero Technologies (PRZO) reported its 2024 financial results with sales up 50.2% to $932,154. A strategic shift towards OEM integrations, a $3.1 million registered direct offering, and defense contract wins underscore this pivot, as detailed in their announcement.
Annovis Bio (ANVS) provided its Q4 and FY 2024 financial results alongside clinical progress in its buntanetap program. The report highlighted reduced R&D expenses, improved net loss per share, and the FDA’s clearance to proceed with a pivotal Phase 3 trial in early Alzheimer’s disease; see the full update.
Technological and Industry Innovations
HUTCHMED (HCM) secured conditional NMPA approval for its breakthrough drug TAZVERIK®, marking a significant advance in treatments for relapsed or refractory follicular lymphoma.
Telix Pharmaceuticals (TLX) won FDA approval for its next‐generation PSMA-PET imaging agent Gozellix®, promising enhanced diagnostics for prostate cancer.
VolitionRx (VNRX) announced promising results for its automated Nu.Q® Cancer immunoassay, which could transform liquid biopsy diagnostics by detecting 21 cancer types with a low false positive rate.
Omeros Corporation (OMER) activated 120 clinical sites across 30 countries for its Phase 3 trial of zaltenibart in paroxysmal nocturnal hemoglobinuria, with BLA submission data anticipated in Q4 2026.
Accelerate Diagnostics (AXDX) submitted its Accelerate WAVE™ system and gram-negative test kit to the FDA for 510(k) clearance, addressing critical sepsis challenges with results delivered in about 4.5 hours.
Strategic Partnerships and Corporate Actions
CGI (GIB) finalized its acquisition of Novatec to expand its European presence, adding over 300 IT and consulting experts to boost its digital service capabilities.
TC BioPharm (TCBP) announced its upcoming delisting from Nasdaq after not meeting the $1.00 minimum bid requirement, with trading set to move to OTC Markets on March 24, 2025.
NGPL PipeCo LLC revealed that Brookfield Infrastructure Partners L.P. will sell its 25% interest to ArcLight Capital Partners, with Kinder Morgan retaining 37.5%, as the deal is expected to close in Q2 2025.
Boeing (BA) secured a landmark contract from the U.S. Air Force to design and deliver a 6th-generation Next-Generation Air Dominance fighter, a critical component of the NGAD Family of Systems.
Lion Group Holding (LGHL) announced plans to adjust its American Depositary Shares ratio from 1:50 to 1:2,500 via a one-for-fifty reverse ADS split, aiming to regain compliance with Nasdaq’s requirements; see the details.
American Express Global Business Travel (GBTG) announced amended terms for its merger agreement to acquire CWT. The revised deal values CWT at $540 million and revises stock price and share issuance details to address regulatory concerns from an antitrust lawsuit, as outlined in the announcement.
Baijiayun Group (RTC) received a Nasdaq delisting notification due to failing to meet the minimum bid price requirement. With a hearing scheduled for April 24, 2025, the company is appealing the decision while its Class A ordinary shares continue trading on the Nasdaq Global Market; further insights are provided in the full report.
Coty Inc. (COTY) divested its 20% stake in SKKN by Kim to SKIMS, marking the conclusion of its partnership with Kim Kardashian. The proceeds will support Coty’s deleveraging strategy as it focuses on broader brand portfolio innovations, details of which are available in the announcement.
Policy and Infrastructure Developments
Shell (SHEL) declared the Final Investment Decision for the Gato do Mato offshore project in Brazil’s Santos Basin—a joint venture with Ecopetrol and TotalEnergies expected to yield up to 120,000 barrels per day from 2029.
ReElement Technologies (AREC) successfully scaled up its SEG+ ore concentrate refining capacity by 50 times using Ligand Assisted Displacement Chromatography, strengthening domestic supply in the critical rare earth chain.
Electra Battery Materials (ELBM) received a Letter of Intent for $20 million in funding from the Canadian Federal Government to complete North America’s first battery-grade cobalt refinery, set to produce 6,500 tonnes of cobalt annually to support EV production.
California American Water (AWK) announced a comprehensive $162 million investment in statewide water and wastewater system upgrades to secure community health and bolster economic vitality.
NioCorp Developments (NB) welcomed President Trump’s Executive Order boosting U.S. critical minerals production. Its Elk Creek Critical Minerals Project in Nebraska is poised to benefit, with talks underway for up to $800 million in debt financing and a potential $10 million grant, as detailed in the full report.
